화학요법 유발성 말초신경병증 치료 시장 : 치료 유형, 투여 경로, 환자 연령층, 치료 기간, 최종사용자별 - 세계 예측(2025-2030년)

The Chemotherapy Induced Peripheral Neuropathy Treatment Market was valued at USD 985.84 million in 2024 and is projected to grow to USD 1,064.12 million in 2025, with a CAGR of 8.21%, reaching USD 1,583.61 million by 2030.

Chemotherapy induced peripheral neuropathy (CIPN) represents a significant challenge that impacts the quality of life for patients undergoing cancer treatments. In this comprehensive summary, we explore the current state of CIPN treatment, underlining how evolving practices and innovative research are reshaping therapeutic approaches. The need for a nuanced understanding of both pharmacological and non-pharmacological treatments has never been greater. This report synthesizes a wealth of data and trends, examining treatment methodologies, regional market dynamics, key company players, and actionable recommendations that support strategic decision-making among industry leaders.

Research into CIPN treatment has intensified, propelled by its direct impact on patient outcomes and overall cost-of-care considerations. In this new landscape, embracing both traditional and breakthrough treatment modalities is essential. Newly emerging therapeutic practices and robust clinical data are driving a more patient-focused paradigm which, in turn, bolsters the integration of innovative strategies into established clinical protocols. As the oncology field continues to evolve, stakeholders must adopt a forward-looking perspective and leverage the latest market insights to address both current challenges and future opportunities in treatment design.

This introduction lays the groundwork for an in-depth examination of the transformative shifts in the treatment landscape, key segmentation insights, and regional as well as corporate competitive dynamics that are defining the market. By presenting an analysis that spans from macro trends to nuanced segmentation factors, this summary serves as a strategic guide designed to empower decision-makers with the intelligence necessary to enhance treatment outcomes and foster innovation in the field of CIPN.

Transformative Shifts in the CIPN Treatment Landscape

Recent years have witnessed transformative shifts that are fundamentally altering the approach to CIPN management. Acute challenges in chemotherapy and subsequent peripheral neuropathy have catalyzed a surge in research and development, resulting in a notable transition towards personalized and multi-disciplinary treatment approaches. Historically, CIPN was managed largely through symptomatic relief with limited targeted therapies. However, the integration of emerging research findings and technological advancements has led to the development of more intricately tailored interventions.

Innovative non-pharmacological treatments have become increasingly recognized for their ability to enhance patient recovery. Techniques such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation are steadily gaining ground as viable alternatives or complements to conventional pharmacological measures. Alongside these strategies, a refined focus on pharmacological treatments including anticonvulsants, antidepressants, and opioids has stimulated further debate on efficacy, safety, and patient suitability. The dual emphasis on advanced non-drug modalities and optimized drug regimens marks a clear shift towards a holistic treatment framework.

Recent strategic initiatives have also redefined care pathways by promoting multi-modal therapies that address both the neurological and systemic implications of cancer treatments. Clinicians are increasingly tailoring treatment plans based on a patient's unique profile rather than adhering solely to a standardized protocol. This individualized approach draws on breakthroughs in pharmacological research as well as rehabilitative practices, ensuring that therapeutic interventions are both scientifically sound and aligned with patient-centric care models.

Furthermore, the evolution of digital health tools and wearable monitoring systems is enabling clinicians to track treatment progress in real time. This data-driven insight not only enhances therapeutic precision but also fosters a more proactive engagement with potential side effects. The blend of technological innovation with clinical expertise is clearly redefining the treatment landscape and heralding a new era marked by adaptive, real-time, and individualized patient care.

The forward momentum in CIPN treatment reflects a broader industry trend towards precision medicine and integrated care. Empowered by emerging data and advanced analytics, healthcare providers are now better positioned to navigate the complexities of treatment regimens while proactively addressing the adverse effects associated with chemotherapy. This paradigm shift is not only transforming patient outcomes, but also setting new benchmarks in clinical research and professional practice.

Key Segmentation Insights Driving Market Differentiation

An in-depth segmentation analysis reveals several critical dimensions that are shaping the competitive and strategic landscape of CIPN treatment. The investigation based on treatment type distinguishes approaches into non-pharmacological and pharmacological categories. Within non-pharmacological interventions, modalities such as acupuncture, physical therapy, and transcutaneous electrical nerve stimulation demonstrate growing prominence due to their ability to offer alternative avenues for symptom management without the systemic side effects often associated with drug treatments. In parallel, pharmacological interventions continue to evolve, particularly with the increasing adoption of anticonvulsants, antidepressants, and opioids that target the underlying neurological disruptions associated with CIPN.

Further segmentation based on the route of administration introduces an added layer of complexity and personalization in treatment strategies. Traditional oral delivery methods continue to be favored for their convenience, while parenteral routes, including intramuscular and intravenous administration, provide targeted delivery options for patients requiring swift therapeutic intervention. Topical applications also play a vital role by offering localized relief without a broad systemic impact, thereby enhancing the versatility of treatment protocols. This detailed exploration of administration routes underscores the commitment to delivering patient-specific methods that optimize both efficacy and safety.

In addition, the segmentation based on patient age group illustrates a distinct differentiation among adults, geriatrics, and pediatrics. Such demographic segmentation is essential since age-related physiological differences necessitate customized approaches that account for metabolism, tolerance, and overall patient resilience. As patient profiles vary widely, this segmentation framework encourages the development of age-appropriate therapies and highlights the need for more refined clinical guidelines.

Another key dimension is therapy duration, which categorizes interventions into long-term and short-term therapies. This segmentation dimension offers clarity on the sustainability and intensity of care that individual patients may require over the course of their treatment journeys. Strategic insights reveal that long-term therapy solutions are crucial for patients with chronic or refractory symptoms, while short-term therapies are effective in acute management scenarios. By understanding these temporal nuances, stakeholders can better allocate resources and design treatment regimens that align with patient needs and clinical outcomes.

Lastly, differentiation based on the end-user setting, which encompasses home care settings, hospitals, and specialty clinics, allows for the customization of interventions based on the care environment. Treatments that are successfully delivered in a controlled hospital environment may require adjustments when adapted for home care or specialized outpatient clinics. These segmentation insights deeply inform strategic decisions related to market positioning, resource allocation, and network collaborations. Collectively, this layered segmentation approach ensures that treatment strategies not only meet broad clinical objectives but are also finely tuned to the diverse needs of a heterogeneous patient population.

Based on Treatment Type, market is studied across Non-Pharmacological Treatments and Pharmacological Treatments. The Non-Pharmacological Treatments is further studied across Acupuncture, Physical Therapy, and Transcutaneous Electrical Nerve Stimulation. The Pharmacological Treatments is further studied across Anticonvulsants, Antidepressants, and Opioids.

Based on Route of Administration, market is studied across Oral, Parenteral, and Topical. The Parenteral is further studied across Intramuscular and Intravenous.

Based on Patient Age Group, market is studied across Adults, Geriatrics, and Pediatrics.

Based on Therapy Duration, market is studied across Long-Term Therapy and Short-Term Therapy.

Based on End-User, market is studied across Home Care Settings, Hospitals, and Specialty Clinics.

Regional Insights: Market Trends Across Key Geographies

An examination of the global landscape reveals that regional trends are central to understanding the evolving market dynamics in CIPN treatment. In the Americas, robust healthcare infrastructure and active investment in cutting-edge research form the bedrock of patient care innovation, driving a substantial uptake of both pharmacological and non-pharmacological treatments. The region's commitment to integrating novel clinical interventions with traditional treatment paradigms has set a benchmark in patient-centered care.

Across Europe, the Middle East and Africa, market dynamics are deeply influenced by ongoing regulatory reforms and increasing investments in medical research. The collaboration between regional academic institutions and healthcare providers is fostering a progressive environment that supports innovative clinical practices. The emphasis on comprehensive patient management through diversified therapeutic channels, along with the modernization of healthcare delivery systems, is markedly impacting clinical outcomes.

Asia-Pacific continues to emerge as a pivotal growth driver with a strong focus on rapid technological adoption and customized healthcare solutions. Increasing public and private investments in state-of-the-art medical infrastructure are catalyzing the development of advanced treatment practices that cater to the unique needs of its diverse population. Market trends in this region underscore a significant commitment to research, as well as the integration of digital health solutions, which is facilitating a seamless blend of traditional and innovative treatment methodologies.

The regional analysis elucidates the need for localized strategies that account for both economic and cultural factors. Each geographic zone offers distinct opportunities and challenges, thereby necessitating tailored approaches that respect local market conditions while leveraging global clinical insights. Industry stakeholders can draw on these regional insights to optimize growth strategies, enhance clinical collaborations, and ultimately, advance the overall standard of care in CIPN treatment.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape: Evaluating Key Industry Players

Within the competitive landscape, several key companies have emerged as frontrunners in CIPN treatment innovation. These industry leaders, including AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., and Asahi Kasei Corporation, have been instrumental in propelling the research, development, and commercialization of breakthrough therapeutic solutions. Further contributions come from Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Eisai Inc., all of which have demonstrated a steadfast commitment to advancing clinical care in this arena.

Other notable players such as F. Hoffmann-La Roche Ltd and GlaxoSmithKline PLC have leveraged extensive research and robust global networks to introduce both innovative drug compounds and supportive non-pharmacological interventions. The strategic initiatives pursued by Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, and Heron Therapeutics, Inc. have provided additional momentum to the market by focusing on patient-centric treatment design and precision medicine approaches. Ipsen Pharma, Kyowa Kirin Co., Ltd., and Merck & Co., Inc. also play pivotal roles, leveraging cutting-edge research to enhance the efficacy of existing treatment paradigms.

Contributions from Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, and Regeneron Pharmaceuticals, Inc. further underscore the importance of cross-collaborative efforts in addressing complex clinical challenges. Leading international pharmaceutical companies such as Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc. are also key players, with their rigorous research and adaptive clinical strategies helping to shape the future of CIPN treatment. The strategic interplay between these companies is fostering a dynamic ecosystem that continuously refines treatment protocols, enhances patient outcomes, and promotes sustainable clinical innovation across the global market.

The report delves into recent significant developments in the Chemotherapy Induced Peripheral Neuropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Bexion Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Eisai Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Grunenthal GmbH, Heron Therapeutics, Inc., Ipsen Pharma, Kyowa Kirin Co., Ltd., Merck & Co., Inc., Neuralace Medical, Novartis AG, Regenacy Pharmaceuticals LLC, Regeneron Pharmaceuticals, Inc., Sanofi S.A., Serpin Pharma, LLC, Takeda Pharmaceutical Company Limited, and Veloxis Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders

Leaders in the healthcare and pharmaceutical sectors are advised to adopt a multi-faceted strategic approach to navigate the evolving CIPN treatment landscape effectively. One recommendation is to invest in robust research and development initiatives that blend groundbreaking clinical trials with real-world evidence. By supporting translational research, organizations can bridge the gap between innovative theory and practical application, thereby ensuring that novel therapies are both effective and accessible.

Another key recommendation is to foster strong partnerships between academic institutions, research organizations, and clinical practitioners. Collaborative efforts that unite diverse areas of expertise can provide the synergies necessary to propel the development of both pharmacological and non-pharmacological treatment options. Furthermore, digitization and advanced data analytics should be embraced to facilitate patient-specific treatment planning, monitor outcomes more accurately, and drive continuous process improvements across the care continuum.

Industry leaders should also consider adopting flexible regulatory strategies that allow for quicker adaptation to new clinical data and technological advancements. Proactive engagement with regulatory bodies can smooth the path to market for emerging therapies, ensuring that groundbreaking treatments reach patients with minimal delays. Additionally, an emphasis on market education and awareness, through initiatives that communicate the benefits and limitations of different treatment modalities, can help healthcare providers integrate new approaches into mainstream clinical practice more seamlessly.

Finally, it is critical to allocate sufficient resources towards enhancing cross-functional expertise within organizations. By cultivating teams that are well-versed in both clinical and commercial aspects, companies can better anticipate market shifts, tailor strategies to evolving patient needs, and ultimately drive long-term value creation. Industry leaders are encouraged to evaluate their current portfolios, reassess strategic priorities, and invest in innovation centers that can serve as incubators for next-generation therapeutic solutions.

Comprehensive Summary and Forward-Looking Perspective

In summary, the analysis presented in this report highlights the multifaceted and evolving nature of CIPN treatment. From the integration of novel non-pharmacological techniques to the advancement of pharmacological interventions, the landscape is clearly defined by a dynamic interplay between innovation and patient-centered care. Detailed segmentation analysis across treatment types, routes of administration, patient age groups, therapy duration, and end-user settings articulates how personalized and adaptable care models are essential for addressing the challenges inherent in managing chemotherapy induced peripheral neuropathy.

Regional insights further cement the role of localized strategies in maximizing treatment efficacy across distinct geographic markets such as the Americas, Europe, Middle East & Africa, and Asia-Pacific. These regions not only embody diverse healthcare ecosystems but also offer unique opportunities for customization and sustainable growth. Furthermore, the competitive landscape-bolstered by the innovative efforts of leading companies such as AbbVie Inc., AlgoTherapeutix, Amgen Inc., Array BioPharma Inc. by Pfizer Inc., Artelo Biosciences, Inc., Asahi Kasei Corporation, and other industry giants-reinforces the importance of cross-collaborative research and strategic partnerships in propelling the future of CIPN treatments.

This comprehensive summary provides a clear and actionable roadmap for industry stakeholders, urging them to harness the power of emerging technologies, foster collaborative research, and remain agile in the face of evolving clinical demands. The confluence of meticulous segmentation insights, regional market dynamics, and corporate innovations collectively serves as a testament to the sector's potential to transform patient care and chart new territories in the treatment of chemotherapy induced peripheral neuropathy.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer globally
    • 5.1.1.2. Growing awareness about chemotherapy induced peripheral neuropathy among healthcare providers
    • 5.1.1.3. Surge in government funding for oncology research worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of drug development processes and research and development activities
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of ergonomic wearables tailored to patients experiencing peripheral neuropathy symptoms
    • 5.1.3.2. Expanding AI technology utilization in developing predictive models for neuropathy risk assessment
  • 5.1.4. Challenges
    • 5.1.4.1. Complexities in neuropathic mechanisms for treatment post-chemotherapy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Treatment Type: Increasing preferences for anticonvulsants and antidepressants due to their dual function in stabilizing nerve activity
  • 5.2.2. End User: Expanding utilization of CIPN in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Treatment Type

• 6.1. Introduction
• 6.2. Non-Pharmacological Treatments
  • 6.2.1. Acupuncture
  • 6.2.2. Physical Therapy
  • 6.2.3. Transcutaneous Electrical Nerve Stimulation
• 6.3. Pharmacological Treatments
  • 6.3.1. Anticonvulsants
  • 6.3.2. Antidepressants
  • 6.3.3. Opioids

7. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
  • 7.3.1. Intramuscular
  • 7.3.2. Intravenous
• 7.4. Topical

8. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Patient Age Group

• 8.1. Introduction
• 8.2. Adults
• 8.3. Geriatrics
• 8.4. Pediatrics

9. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Therapy Duration

• 9.1. Introduction
• 9.2. Long-Term Therapy
• 9.3. Short-Term Therapy

10. Chemotherapy Induced Peripheral Neuropathy Treatment Market, by End-User

• 10.1. Introduction
• 10.2. Home Care Settings
• 10.3. Hospitals
• 10.4. Specialty Clinics

11. Americas Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. NYU Pain Research Center Receives NIH Grant to study chemotherapy-related pain
  • 14.3.2. FDA cleared Artelo Biosciences' IND application for ART26.12
  • 14.3.3. Serpin Pharma and HekaBio's strategic partnership centers on developing SP163M
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AlgoTherapeutix
• 3. Amgen Inc.
• 4. Array BioPharma Inc. by Pfizer Inc.
• 5. Artelo Biosciences, Inc.
• 6. Asahi Kasei Corporation
• 7. Astellas Pharma Inc.
• 8. Bexion Pharmaceuticals, Inc.
• 9. Bristol-Myers Squibb Company
• 10. Eisai Inc.
• 11. F. Hoffmann-La Roche Ltd
• 12. GlaxoSmithKline PLC
• 13. Glenmark Pharmaceuticals Ltd.
• 14. Grunenthal GmbH
• 15. Heron Therapeutics, Inc.
• 16. Ipsen Pharma
• 17. Kyowa Kirin Co., Ltd.
• 18. Merck & Co., Inc.
• 19. Neuralace Medical
• 20. Novartis AG
• 21. Regenacy Pharmaceuticals LLC
• 22. Regeneron Pharmaceuticals, Inc.
• 23. Sanofi S.A.
• 24. Serpin Pharma, LLC
• 25. Takeda Pharmaceutical Company Limited
• 26. Veloxis Pharmaceuticals, Inc.